Abstract 60P
Background
The studies on hypo-fractionation for GBM showed 5-12 months median overall survivals not inferior to standard fractionation protocols. We aimed to describe the feasibility of extreme hypo fractionation combined with temozolamide for newly diagnosed and recurrent GBM.
Methods
During Dec 2015- Dec 2017, 60 patients of biopsy proven GBM were retrospectively scrutinized and were analysed. PTV was defined on FLAIR/T2 signal coverage with 4 mm margin and GTV was defined as contrast enhanced tumor. PTV was prescribed with 5 Gy (range: 4.5-6 Gy) in five fractions at isocenter and GTV was prescribed as single fraction SRS as 8 Gy (range: 6-12 Gy) at 75% (range: 65-90%) isodose line. Radiation was completed in 8 days. Temozolamide was given as 100mg daily for 8 days.
Results
Mean age was 45 years (range: 22- 74 years). 40(66.66%) patients were male and 20(33.33%) were female. CR was found in 07 (11.66%) patients, PR was seen in 28 (46.66%) patients. SD was observed in 20 (33.33%) patients. 05 (8.33%) had PD during first 3-4 months. Treatment was tolerated very well. Only 5 patients used corticosteroids for 3 months. Median follow-up time was 24 months (range: 08-32 months). Median survival in newly diagnosed patients was 12.5 months (range: 4.5 -16 months), while in recurrent cases it was 8.5 months (range: 3 -11 months).
Conclusions
Extreme hypo-fractionation combined with temozolamide is safe and an effective approach to manage GBM cases and survivals are also comparable to the standard approaches. Further randomized studies are warranted to establish its regular use.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract